| Español |
Last reviewed 4/19/2021
UCSF Health is following public health guidance to pause the use of the Johnson & Johnson (Janssen) COVID-19 vaccine at all of it sites as of April 13, 2021.
The U.S. Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) made its recommendation in light of six cases of a rare type of blood clot that occurred after more than 6.8 million doses of the Johnson & Johnson vaccine were administered across the United States.
All six cases occurred among women between the ages of 18 and 48, with symptoms appearing 6 to 13 days after they received the Johnson & Johnson vaccine. The CDC and FDA are reviewing data regarding the cases to determine whether it is safe to continue to provide the vaccine, the CDC and FDA said in a joint statement.
To date, UCSF Health has administered 2,647 Johnson & Johnson vaccinations since it began administering the vaccine on March 12, 2021. No UCSF Health patients have reported any severe symptoms after receiving the vaccine. Patients who received a Johnson & Johnson vaccine through UCSF and have questions or concerns may call their primary care provider or the COVID-19 hotline at 415-514-7328.
The CDC advises anyone experiencing severe symptoms, including shortness of breath, confusion and severe headaches, within three weeks after the Johnson & Johnson vaccination should go to the Emergency Department and inform their provider.
Pending further guidance from the CDC, UCSF is pausing all Johnson & Johnson vaccinations for its hospitalized patients, homebound patients, and at community vaccination sites, including the City College San Francisco site.
UCSF Health continues to provide the Pfizer and Moderna vaccines. UCSF Health highly recommends COVID-19 vaccination, which has been proven to protect against severe illness and death from COVID-19.